August 5 2005

Boehringer Ingelheim Pharmaceuticals' Mobic is a popularly prescribed drug that is considered by many experts to be chemically similar to the recently banned Cox- inhibitors. Mobic may be more dangerous than the recently withdrawn Vioxx. A veteran FDA scientist told a recent FDA safety panel that Mobic displayed a slightly higher rate of cardiac disease than that seen in Vioxx users.

This information is in a yet-to-be-published study prepared by the FDA, according to David Graham, Associate Director for Science and Medicine at the FDA's Office of Drug Safety.

Since Vioxx was banned from the US Market, Mobic has become the number one prescribed painkiller in its place.

The FDA's Graham, along with other scientists outside the FDA, analyzed data collected from California's Medicaid program covering more than 15,000 heart attack patients, making it the largest study to date on such side effects. It was discerned that the statistical risk of heart attack was 1.37% for Mobic, compared to 1.32% with Vioxx and 1.09% with Celebrex.

Interestingly, even though Mobic is considered a Cox-2 inhibitor in most countries, in the United States it remains classified as a Non-Steroidal Anti-Inflammatory (NSAID). Yet numerous experts say that its chemical structure and physiological nature is very similar to that of the troublesome Cox-2 medications and that it should be classified as one and likewise, banned.

If you or a loved one suffered a cardiac event while taking Mobic under a doctor's orders, please complete the form below.

Register your Mobic Complaint

If you or a loved one has suffered from heart attack or stroke, you may qualify for damages or remedies that may be awarded in a possible class action lawsuit. Please fill in the form to the right to submit your complaint and we will have a lawyer review your Mobic complaint.

At, it is our goal to keep you informed about important legal cases and settlements. We are dedicated to helping you resolve your legal complaints.